Joana Goncalves Sells 7,000 Shares of Oruka Therapeutics (NASDAQ:ORKA) Stock

Oruka Therapeutics, Inc. (NASDAQ:ORKA) insider Joana Goncalves sold 7,000 shares of the business’s stock in a transaction on Friday, May 15th. The shares were sold at an average price of $61.85, for a total transaction of $432,950.00. Following the transaction, the insider directly owned 33,377 shares in the company, valued at approximately $2,064,367.45. The trade was a 17.34% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Joana Goncalves also recently made the following trade(s):

• On Wednesday, April 15th, Joana Goncalves sold 7,000 shares of Oruka Therapeutics stock. The shares were sold at an average price of $66.12, for a total transaction of $462,840.00.
• On Monday, March 16th, Joana Goncalves sold 7,641 shares of Oruka Therapeutics stock. The shares were sold at an average price of $40.91, for a total transaction of $312,593.31.
• On Tuesday, February 17th, Joana Goncalves sold 7,000 shares of Oruka Therapeutics stock. The shares were sold at an average price of $32.37, for a total transaction of $226,590.00.

Oruka Therapeutics Stock Down 3.1%

Oruka Therapeutics stock traded down $1.97 during mid-day trading on Friday, reaching $61.93. 1,392,935 shares of the company traded hands, compared to its average volume of 2,363,309. The firm’s 50 day moving average price is $55.17 and its 200 day moving average price is $39.33. Oruka Therapeutics, Inc. has a 52-week low of $9.40 and a 52-week high of $91.00.

Oruka Therapeutics (NASDAQ:ORKA) last issued its quarterly earnings data on Wednesday, May 13th. The company reported ($0.48) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.52) by $0.04. Research analysts anticipate that Oruka Therapeutics, Inc. will post -2.2 EPS for the current year.

Institutional Trading of Oruka Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the business. Legal & General Group Plc purchased a new stake in shares of Oruka Therapeutics in the 2nd quarter worth about $28,000. BNP Paribas Financial Markets grew its position in Oruka Therapeutics by 464.0% during the 2nd quarter. BNP Paribas Financial Markets now owns 2,803 shares of the company’s stock valued at $31,000 after purchasing an additional 2,306 shares during the last quarter. Royal Bank of Canada grew its position in Oruka Therapeutics by 47.2% during the 4th quarter. Royal Bank of Canada now owns 1,139 shares of the company’s stock valued at $34,000 after purchasing an additional 365 shares during the last quarter. Los Angeles Capital Management LLC purchased a new stake in Oruka Therapeutics during the 4th quarter valued at about $37,000. Finally, PNC Financial Services Group Inc. purchased a new stake in Oruka Therapeutics during the 3rd quarter valued at about $39,000. 56.44% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on ORKA. HC Wainwright upped their target price on shares of Oruka Therapeutics from $75.00 to $120.00 and gave the stock a “buy” rating in a research report on Wednesday, April 29th. Wedbush set a $165.00 target price on shares of Oruka Therapeutics in a research report on Monday, April 27th. BTIG Research reaffirmed a “buy” rating and issued a $151.00 target price on shares of Oruka Therapeutics in a research report on Thursday. Stifel Nicolaus upped their target price on shares of Oruka Therapeutics from $47.00 to $72.00 and gave the stock a “buy” rating in a research report on Friday, March 13th. Finally, Guggenheim set a $200.00 target price on shares of Oruka Therapeutics and gave the stock a “buy” rating in a research report on Monday, April 27th. Ten research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $120.80.

About Oruka Therapeutics

Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company’s proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company’s lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.